Format

Send to

Choose Destination
J Clin Virol. 2016 Mar;76 Suppl 1:S14-S21. doi: 10.1016/j.jcv.2015.09.014. Epub 2015 Oct 8.

VALGENT: A protocol for clinical validation of human papillomavirus assays.

Author information

1
Unit of Cancer Epidemiology & Belgian Cancer Centre, Scientific Institute of Public Health, J. Wytsmanstreet 14, B1050 Brussels, Belgium. Electronic address: marc.arbyn@wiv-isp.be.
2
Department of Molecular Pathology, AML Laboratory, Sonic Healthcare, Antwerp, Belgium.
3
Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK.
4
Division Molecular Diagnostics of Oncogenic Infections, Research Program Infection, Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
5
DDL Diagnostic Laboratory, Rijswijk, the Netherlands.
6
French HPV Reference Laboratory, Institut Pasteur, Paris, France.
7
International Agency for Research on Cancer, Lyon, France.
8
Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
9
Department of Pathology and Clinical Research Center, Copenhagen University Hospital, Hvidovre, Denmark.

Abstract

BACKGROUND:

Testing for high-risk HPV is more effective in primary cervical cancer screening than the cytological examination of a Pap smear. Separate genotyping may be useful for triage in both HPV-based and cytology-based screening. Only clinically validated tests should be used in clinical practice.

OBJECTIVES:

VALGENT is a study framework for test comparison and validation of HPV assays in general and HPV genotyping tests in particular according to clinically relevant outcomes and for clinical applications endorsed by scientific evidence.

STUDY DESIGN:

VALGENT involves the collation of fresh or archived cervical cell specimen from women attending routine screening supplemented with cytologically abnormal samples. Multiple aliquots of residual material are sent from a central laboratory to participating laboratories for testing with novel HPV assays with limited, extended or full genotyping capacity. Outcomes are derived from screening and pathology registries. Each VALGENT panel includes an assay already validated for screening. A series of accuracy and concordance statistics were generated.

RESULTS:

Currently, two VALGENT study rounds, originated from laboratories in Antwerp (Belgium) and Edinburgh (Scotland), were completed. Two new assays (G5+/6+ PCR-LMNX and Xpert HPV) were validated for screening by showing similar accuracy for cervical precancer as the standard comparator test. For two other tests (BD Onclarity, PapilloCheck) validation was confirmed. Inter-test agreement was high although certain type-specific discordances were observed which warrant further analysis.

CONCLUSION:

VALGENT extends current guidelines for high-risk HPV test validation in cervical cancer screening and has produced a large study resource for test comparison. More robust procedures of sample selection and handling and integration with the global WHO reference laboratory network focusing on analytical accuracy, may result in the generation of an international standard and a formalized system for clinical validation of HPV assays and quality control in HPV-based screening.

KEYWORDS:

Cervical cancer; Cervical cancer screening; Diagnostic test accuracy; Human papillomavirus; Quality control; Test validation

PMID:
26522865
DOI:
10.1016/j.jcv.2015.09.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center